Antiangiogenic effect of licochalcone A

Area of Science:

• Pharmacology
• Cancer Biology
• Biochemistry

Background:

• Licochalcone A (LicA) is a phenolic compound from Glycyrrhiza inflata with known antitumor effects.
• Previous research indicated LicA modulates inflammatory responses in macrophages.
• Angiogenesis is critical for tumor development and progression.

Purpose of the Study:

• To investigate the antiangiogenic potential of LicA.
• To determine if LicA inhibits angiogenesis in vitro and in vivo.

Main Methods:

• Assessed LicA's effects on human umbilical vascular endothelial cell (HUVEC) proliferation, migration, and tube formation.
• Evaluated LicA's impact on microvessel growth in rat aortic rings.
• Examined LicA's efficacy against CT-26 colon cancer xenografts in mice.
• Investigated the molecular mechanism involving vascular endothelial growth factor receptor (VEGFR)-2 signaling.

Main Results:

• LicA significantly inhibited HUVEC proliferation, migration, and tube formation.
• LicA reduced microvessel growth in rat aortic rings.
• In vivo, LicA suppressed tumor growth, decreasing proliferation markers (CD31, Ki-67) and increasing apoptosis.
• LicA treatment led to down-regulation of VEGFR-2 activation.

Conclusions:

• LicA demonstrates significant antiangiogenic activity both in vitro and in vivo.
• The antiangiogenic effect of LicA may be mediated by the inhibition of VEGF/VEGFR-2 signaling.
• LicA holds potential for therapeutic strategies targeting angiogenesis-dependent tumors.